- American City Business Journals•4 days ago
The Chinese group of stem-cell research companies that made financing available to Rancho Cordova-based Cesca Therapeutics Inc. earlier this year is now the majority owner of the company. Boyalife Group invested $15 million in regenerative medicine company Cesca in January, as the publicly traded developer of regenerative medicine technology was running short of cash to operate and to perform clinical trials. The deal was structured with Boyalife buying $2.5 million in Cesca stock priced at $3.40 a share and $12.5 million in convertible debt bearing 22 percent interest.
- GlobeNewswire•6 days ago
RANCHO CORDOVA, Calif., Aug. 24, 2016-- Cesca Therapeutics Inc., an autologous cell-based regenerative medicine company, today announced that the Company has converted a senior secured three year convertible ...
- American City Business Journals•26 days ago
Rancho Cordova-based Cesca Therapeutics Inc. is raising $2.5 million in a registered direct stock offering to institutional investors, taking on funds that may give it more time to conduct clinical trials of its regenerative medical technology before the company is at risk of running out of cash. Proceeds raised in the offering will be used for general working capital purposes, Cesca (KOOL) said in a statement. Cesca agreed to sell 600,000 shares priced at $4.10 each in the private placement to institutional investors who were not immediately identified.
Cesca Therapeutics Inc. (KOOL)
NasdaqCM - NasdaqCM Real Time Price. Currency in USD
|Bid||3.94 x 200|
|Ask||4.01 x 200|
|Day's Range||3.89 - 4.22|
|52wk Range||1.60 - 14.80|
|1y Target Est||N/A|
Trade prices are not sourced from all markets
|P/E Ratio (ttm)||-0.51|
|Avg Vol (3m)||587,437|
|Dividend & Yield||N/A (N/A)|